Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Roivant Sciences (ROIV) PT Raised to $26 at Citi
November 10, 2025 3:58 PM ESTCiti analyst Samantha Semenkow raised the price target on Roivant Sciences (NASDAQ: ROIV) to $26.00 (from $25.00) while maintaining a Buy rating.
Removes 90-Day Upside Catalyst Watch... More